Back to News
Market Impact: 0.2
AbbVie Presents Detailed Phase 1 Data for ABBV-295, a Long-Acting Amylin Analog, Demonstrating Favorable Tolerability and Pharmacokinetic Profile at EASD 2026
Source: PR Newswire
Healthcare & BiotechCompany Fundamentals
ABBV-295 showed an approximately 11- to 12-day half-life and dose-proportional increases in plasma exposure in detailed findings slated for oral presentation. The pharmacokinetic profile supports evaluating less-frequent dosing schedules beyond weekly administration, including every-other-week dosing, representing an encouraging development-stage signal.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
ABBV0.45
More News
- AbbVie’s zumilokibart meets phase 2 atopic dermatitis endpoint
- AbbVie presents phase 1 data for obesity drug ABBV-295
- Tencent leases 100,000 chips from Oracle for $7 bln- FT
- RAM supply set to worsen, says Micron, as CEO celebrates ‘much higher’ prices
- Why is Nidec stock plunging today?
- Why is Kioxia stock rallying today?